Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
2021 · The Lancet Oncology · 251 citations
https://doi.org/10.1016/s1470-2045(21)00471-x
P
Paul Shaw
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
53
Papers
1.2K
Citations
13
h-index
15
i10-index
Paul Shaw is an academic researcher from Chinese University of Hong Kong. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment & Cancer Immunotherapy and Biomarkers. The author has an h-index of 13, co-authored 46 publications.
Papers by this author
worksFunctional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium
2016 · Oncogene · 28 citations
https://doi.org/10.1038/onc.2016.342
Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apcmin/+ mouse
2011 · British Journal of Cancer · 10 citations
https://doi.org/10.1038/bjc.2011.291
1232: Modern era radical radiotherapy toxicity: a preliminary CONCORDE analysis of the calibration arm
2024 · Radiotherapy and Oncology · 0 citations
https://doi.org/10.1016/s0167-8140(24)01671-2
P4.14C.08 HIT-MESO: Hemithoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma. UK National Proton Radiotherapy Study
2024 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2024.09.749
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology
2025 · British Journal of Cancer · 0 citations
https://doi.org/10.1038/s41416-025-03252-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat